CY2542B1 - Epothilone c, d, e and f, production process, and their use as cytostatic as well as phytosanitary agents - Google Patents
Epothilone c, d, e and f, production process, and their use as cytostatic as well as phytosanitary agentsInfo
- Publication number
- CY2542B1 CY2542B1 CY0500058A CY0500058A CY2542B1 CY 2542 B1 CY2542 B1 CY 2542B1 CY 0500058 A CY0500058 A CY 0500058A CY 0500058 A CY0500058 A CY 0500058A CY 2542 B1 CY2542 B1 CY 2542B1
- Authority
- CY
- Cyprus
- Prior art keywords
- epothilone
- methanol
- cytostatic
- well
- production process
- Prior art date
Links
- 239000003795 chemical substances by application Substances 0.000 title 1
- 239000000824 cytostatic agent Substances 0.000 title 1
- 230000001085 cytostatic effect Effects 0.000 title 1
- BEFZAMRWPCMWFJ-QPFHJNJHSA-N epothilone c Chemical compound O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCC\C=C/CC1C(\C)=C\C1=CSC(C)=N1 BEFZAMRWPCMWFJ-QPFHJNJHSA-N 0.000 title 1
- XOZIUKBZLSUILX-UKMAFROXSA-N epothilone d Chemical compound O1C(=O)C[C@@H](O)C(C)(C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)CCC\C(C)=C/C[C@@H]1C(\C)=C\C1=CSC(C)=N1 XOZIUKBZLSUILX-UKMAFROXSA-N 0.000 title 1
- FCCNKYGSMOSYPV-OKOHHBBGSA-N epothilone e Chemical compound C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(CO)=N1 FCCNKYGSMOSYPV-OKOHHBBGSA-N 0.000 title 1
- UKIMCRYGLFQEOE-RGJAOAFDSA-N epothilone f Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(CO)=N1 UKIMCRYGLFQEOE-RGJAOAFDSA-N 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 abstract 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 abstract 3
- 239000011347 resin Substances 0.000 abstract 3
- 229920005989 resin Polymers 0.000 abstract 3
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 abstract 2
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 abstract 2
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 abstract 1
- 229920005654 Sephadex Polymers 0.000 abstract 1
- 239000012507 Sephadex™ Substances 0.000 abstract 1
- 241000862997 Sorangium cellulosum Species 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 238000004587 chromatography analysis Methods 0.000 abstract 1
- 229930013356 epothilone Natural products 0.000 abstract 1
- QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 abstract 1
- 150000003883 epothilone derivatives Chemical class 0.000 abstract 1
- 238000002955 isolation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000000926 separation method Methods 0.000 abstract 1
- 238000000638 solvent extraction Methods 0.000 abstract 1
- 238000005406 washing Methods 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
- A01N43/74—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,3
- A01N43/78—1,3-Thiazoles; Hydrogenated 1,3-thiazoles
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
- A01N63/20—Bacteria; Substances produced thereby or obtained therefrom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
- C12P17/167—Heterorings having sulfur atoms as ring heteroatoms, e.g. vitamin B1, thiamine nucleus and open chain analogs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
- C12P17/181—Heterocyclic compounds containing oxygen atoms as the only ring heteroatoms in the condensed system, e.g. Salinomycin, Septamycin
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biotechnology (AREA)
- Environmental Sciences (AREA)
- Dentistry (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Oncology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Silicon Polymers (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epoxy Compounds (AREA)
- Steroid Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19647580 | 1996-11-18 | ||
| DE19707506 | 1997-02-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY2542B1 true CY2542B1 (en) | 2006-06-28 |
Family
ID=26031383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY0500058A CY2542B1 (en) | 1996-11-18 | 2005-10-26 | Epothilone c, d, e and f, production process, and their use as cytostatic as well as phytosanitary agents |
Country Status (23)
| Country | Link |
|---|---|
| US (6) | US7067544B2 (cs) |
| EP (2) | EP0941227B2 (cs) |
| JP (1) | JP4274583B2 (cs) |
| KR (1) | KR100538095B1 (cs) |
| CN (2) | CN100344627C (cs) |
| AT (2) | ATE408612T1 (cs) |
| AU (1) | AU753546B2 (cs) |
| BR (1) | BR9713363B1 (cs) |
| CA (1) | CA2269118C (cs) |
| CY (1) | CY2542B1 (cs) |
| CZ (2) | CZ303422B6 (cs) |
| DE (2) | DE59711647D1 (cs) |
| DK (2) | DK1367057T3 (cs) |
| ES (2) | ES2312695T3 (cs) |
| HU (1) | HU229833B1 (cs) |
| IL (1) | IL129558A (cs) |
| NO (1) | NO319984B1 (cs) |
| NZ (1) | NZ335383A (cs) |
| PL (1) | PL193229B1 (cs) |
| PT (2) | PT941227E (cs) |
| RU (1) | RU2198173C2 (cs) |
| TW (1) | TW408119B (cs) |
| WO (1) | WO1998022461A1 (cs) |
Families Citing this family (183)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0873341B1 (de) | 1995-11-17 | 2003-09-10 | Gesellschaft für biotechnologische Forschung mbH (GBF) | Epothilonderivate, herstellung und verwendung |
| US5969145A (en) * | 1996-08-30 | 1999-10-19 | Novartis Ag | Process for the production of epothilones and intermediate products within the process |
| DE59711647D1 (de) * | 1996-11-18 | 2004-06-24 | Biotechnolog Forschung Gmbh | Epothilon d, dessen herstellung und dessen verwendung als cytostatisches mittel bzw. als pflanzenschutzmittel |
| US6204388B1 (en) | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US6867305B2 (en) | 1996-12-03 | 2005-03-15 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| AU756699B2 (en) | 1996-12-03 | 2003-01-23 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| US6380394B1 (en) | 1996-12-13 | 2002-04-30 | The Scripps Research Institute | Epothilone analogs |
| US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
| US6660758B1 (en) | 1996-12-13 | 2003-12-09 | The Scripps Research Institute | Epothilone analogs |
| US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
| US6320045B1 (en) | 1997-12-04 | 2001-11-20 | Bristol-Myers Squibb Company | Process for the reduction of oxiranyl epothilones to olefinic epothilones |
| US6365749B1 (en) | 1997-12-04 | 2002-04-02 | Bristol-Myers Squibb Company | Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs |
| US6683100B2 (en) | 1999-01-19 | 2004-01-27 | Novartis Ag | Organic compounds |
| US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
| FR2775187B1 (fr) | 1998-02-25 | 2003-02-21 | Novartis Ag | Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo |
| US6498257B1 (en) * | 1998-04-21 | 2002-12-24 | Bristol-Myers Squibb Company | 2,3-olefinic epothilone derivatives |
| US6399638B1 (en) | 1998-04-21 | 2002-06-04 | Bristol-Myers Squibb Company | 12,13-modified epothilone derivatives |
| DE19820599A1 (de) | 1998-05-08 | 1999-11-11 | Biotechnolog Forschung Gmbh | Epothilonderivate, Verfahren zu deren Herstellung und deren Verwendung |
| NZ508326A (en) * | 1998-06-18 | 2003-10-31 | Novartis Ag | A polyketide synthase and non ribosomal peptide synthase genes, isolated from a myxobacterium, necessary for synthesis of epothiones A and B |
| DE19826988A1 (de) * | 1998-06-18 | 1999-12-23 | Biotechnolog Forschung Gmbh | Epothilon-Nebenkomponenten |
| DE19846493A1 (de) * | 1998-10-09 | 2000-04-13 | Biotechnolog Forschung Gmbh | DNA-Sequenzen für die enzymatische Synthese von Polyketid- oder Heteropolyketidverbindungen |
| AU768220B2 (en) | 1998-11-20 | 2003-12-04 | Kosan Biosciences, Inc. | Recombinant methods and materials for producing epothilone and epothilone derivatives |
| US6410301B1 (en) | 1998-11-20 | 2002-06-25 | Kosan Biosciences, Inc. | Myxococcus host cells for the production of epothilones |
| US6780620B1 (en) | 1998-12-23 | 2004-08-24 | Bristol-Myers Squibb Company | Microbial transformation method for the preparation of an epothilone |
| EP1140928A4 (en) * | 1998-12-23 | 2002-10-02 | Bristol Myers Squibb Co | MICROBIAL CONVERSION METHOD FOR PRODUCING AN EPOTHILONE |
| US6596875B2 (en) | 2000-02-07 | 2003-07-22 | James David White | Method for synthesizing epothilones and epothilone analogs |
| DK1157023T3 (da) * | 1999-02-22 | 2004-03-29 | Bristol Myers Squibb Co | C-21-modificerede epothiloner |
| US6291684B1 (en) | 1999-03-29 | 2001-09-18 | Bristol-Myers Squibb Company | Process for the preparation of aziridinyl epothilones from oxiranyl epothilones |
| US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| PL215901B1 (pl) | 1999-04-15 | 2014-02-28 | Bristol Myers Squibb Co | Cykliczny inhibitor bialkowych kinaz tyrozynowych, jego zastosowanie oraz kompozycja farmaceutyczna zawierajaca taki zwiazek |
| EP2289549A3 (en) | 1999-10-01 | 2011-06-15 | Immunogen, Inc. | Immunoconjugates for treating cancer |
| US6518421B1 (en) * | 2000-03-20 | 2003-02-11 | Bristol-Myers Squibb Company | Process for the preparation of epothilone analogs |
| US6593115B2 (en) | 2000-03-24 | 2003-07-15 | Bristol-Myers Squibb Co. | Preparation of epothilone intermediates |
| EP1320611B1 (en) * | 2000-04-28 | 2005-11-09 | Kosan Biosciences, Inc. | Heterologous production of polyketides |
| US6998256B2 (en) | 2000-04-28 | 2006-02-14 | Kosan Biosciences, Inc. | Methods of obtaining epothilone D using crystallization and /or by the culture of cells in the presence of methyl oleate |
| US6589968B2 (en) | 2001-02-13 | 2003-07-08 | Kosan Biosciences, Inc. | Epothilone compounds and methods for making and using the same |
| UA75365C2 (en) | 2000-08-16 | 2006-04-17 | Bristol Myers Squibb Co | Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon |
| GB0029895D0 (en) | 2000-12-07 | 2001-01-24 | Novartis Ag | Organic compounds |
| WO2002058699A1 (en) * | 2001-01-25 | 2002-08-01 | Bristol-Myers Squibb Company | Pharmaceutical forms of epothilones for oral administration |
| CZ20032021A3 (cs) | 2001-01-25 | 2004-05-12 | Bristol@Myersásquibbácompany | Způsoby podávání analogů epothilonu při léčbě rakoviny |
| SK8552003A3 (en) | 2001-01-25 | 2004-06-08 | Bristol Myers Squibb Co | Parenteral formulation containing epothilone analogs |
| US6893859B2 (en) | 2001-02-13 | 2005-05-17 | Kosan Biosciences, Inc. | Epothilone derivatives and methods for making and using the same |
| JP2004522774A (ja) | 2001-02-20 | 2004-07-29 | ブリストル−マイヤーズ スクイブ カンパニー | エポチロン誘導体を用いる耐性腫瘍の治療 |
| CN1610549A (zh) | 2001-02-20 | 2005-04-27 | 布里斯托尔-迈尔斯斯奎布公司 | 用于治疗难治肿瘤的埃坡霉素衍生物 |
| NZ527764A (en) | 2001-02-27 | 2006-01-27 | Novartis Ag | Combination comprising a signal transduction inhibitor and an epothilone derivative |
| DE60213884T2 (de) | 2001-02-27 | 2007-02-22 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Verfahren zur Herstellung von Epothilonen |
| ES2384789T3 (es) | 2001-03-14 | 2012-07-12 | Bristol-Myers Squibb Company | Combinación de un análogo de epotilona y agentes quimioterapéuticos para el tratamiento de enfermedades proliferativas |
| JP2004532888A (ja) | 2001-06-01 | 2004-10-28 | ブリストル−マイヤーズ スクイブ カンパニー | エポチロン誘導体 |
| TWI315982B (en) | 2001-07-19 | 2009-10-21 | Novartis Ag | Combinations comprising epothilones and pharmaceutical uses thereof |
| DE10138347A1 (de) * | 2001-08-03 | 2003-02-27 | Schering Ag | Geschützte 3,5-Dihydroxy-2,2-dimethyl-valeronitrile für die Synthese von Epothilonen- und Derivaten und Verfahren zur Herstellung |
| TWI287986B (en) * | 2001-12-13 | 2007-10-11 | Novartis Ag | Use of Epothilones for the treatment of the carcinoid syndrome |
| US6884608B2 (en) | 2001-12-26 | 2005-04-26 | Bristol-Myers Squibb Company | Compositions and methods for hydroxylating epothilones |
| CA2471509A1 (en) | 2002-01-14 | 2003-07-17 | Novartis Ag | Combinations comprising epothilones and anti-metabolites |
| TW200303202A (en) | 2002-02-15 | 2003-09-01 | Bristol Myers Squibb Co | Method of preparation of 21-amino epothilone derivatives |
| WO2003077903A1 (en) | 2002-03-12 | 2003-09-25 | Bristol-Myers Squibb Company | C12-cyano epothilone derivatives |
| ATE452896T1 (de) | 2002-03-12 | 2010-01-15 | Bristol Myers Squibb Co | C3-cyanoepothilonderivate |
| TW200403994A (en) | 2002-04-04 | 2004-03-16 | Bristol Myers Squibb Co | Oral administration of EPOTHILONES |
| TW200400191A (en) | 2002-05-15 | 2004-01-01 | Bristol Myers Squibb Co | Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives |
| US7405234B2 (en) | 2002-05-17 | 2008-07-29 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
| AU2003243561A1 (en) | 2002-06-14 | 2003-12-31 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| KR100972542B1 (ko) * | 2002-07-29 | 2010-07-28 | 옵티머 파마슈티칼즈, 인코포레이티드 | 티아쿠미신 제조법 |
| PT1767535E (pt) * | 2002-08-23 | 2010-02-24 | Sloan Kettering Inst Cancer | Síntese de epotilonas, respectivos intermediários, análogos e suas utilizações |
| US6921769B2 (en) | 2002-08-23 | 2005-07-26 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| EP2287168B1 (en) | 2002-09-23 | 2013-02-13 | Bristol-Myers Squibb Company | Methods for the preparation, isolation and purification of epothilone B, and X-ray crystal structures of epothilone B |
| ES2279139T3 (es) * | 2002-10-15 | 2007-08-16 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Uso de los derivados de epotilona para el tratamiento del hiperparatiroidismo. |
| EP1567487A4 (en) | 2002-11-15 | 2005-11-16 | Bristol Myers Squibb Co | OPEN-CHAINED, PROLYL-FROSTED MODULATORS OF ANDROGEN RECEPTOR FUNCTION |
| CN101177425B (zh) * | 2003-01-28 | 2012-07-18 | 北京华昊中天生物技术有限公司 | 一类新型埃坡霉素化合物及其制备方法和用途 |
| US20050171167A1 (en) | 2003-11-04 | 2005-08-04 | Haby Thomas A. | Process and formulation containing epothilones and analogs thereof |
| EP1559447A1 (en) | 2004-01-30 | 2005-08-03 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism |
| US7820702B2 (en) | 2004-02-04 | 2010-10-26 | Bristol-Myers Squibb Company | Sulfonylpyrrolidine modulators of androgen receptor function and method |
| US7378426B2 (en) | 2004-03-01 | 2008-05-27 | Bristol-Myers Squibb Company | Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 |
| US7625923B2 (en) | 2004-03-04 | 2009-12-01 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
| US7696241B2 (en) | 2004-03-04 | 2010-04-13 | Bristol-Myers Squibb Company | Bicyclic compounds as modulators of androgen receptor function and method |
| NZ549925A (en) | 2004-04-07 | 2010-08-27 | Novartis Ag | Inhibitors of IAP |
| US10675326B2 (en) | 2004-10-07 | 2020-06-09 | The Board Of Trustees Of The University Of Illinois | Compositions comprising cupredoxins for treating cancer |
| WO2006055742A1 (en) * | 2004-11-18 | 2006-05-26 | Bristol-Myers Squibb Company | Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof |
| ATE397442T1 (de) * | 2004-11-18 | 2008-06-15 | Bristol Myers Squibb Co | Magensaftresistent beschichtetes pellet mit ixabepilon |
| US20060121511A1 (en) | 2004-11-30 | 2006-06-08 | Hyerim Lee | Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| KR20080054417A (ko) | 2005-09-27 | 2008-06-17 | 노파르티스 아게 | 카르복시아민 화합물 및 ｈｄａｃ 의존성 질환의 치료에있어서의 그의 용도 |
| PT2275103E (pt) | 2005-11-21 | 2014-07-24 | Novartis Ag | Inibidores de mtor para o tratamento de tumores endócrinos |
| GB0605120D0 (en) | 2006-03-14 | 2006-04-26 | Novartis Ag | Organic Compounds |
| CA2647565A1 (en) | 2006-03-31 | 2007-10-18 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents |
| AU2007240548A1 (en) | 2006-04-05 | 2007-11-01 | Novartis Ag | Combinations of therapeutic agents for treating cancer |
| BRPI0709749A2 (pt) | 2006-04-05 | 2011-07-26 | Novartis Ag | combinaÇÕes de agentes terapÊuticos para tratamento de cÂncer |
| NZ572299A (en) | 2006-05-09 | 2010-07-30 | Novartis Ag | Combination comprising a substituted 3,5-diphenyl-1,2,4-triazole and a platinum compound and use thereof |
| WO2008037477A1 (en) | 2006-09-29 | 2008-04-03 | Novartis Ag | Pyrazolopyrimidines as p13k lipid kinase inhibitors |
| JP2010511408A (ja) | 2006-12-04 | 2010-04-15 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ | 癌をＣｐＧリッチＤＮＡおよびキュプレドキシンで治療するための組成物および方法 |
| JP2010518123A (ja) | 2007-02-08 | 2010-05-27 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ | 癌をキュプレドキシンで予防するための組成物および方法 |
| EP2491923A3 (en) | 2007-02-15 | 2012-12-26 | Novartis AG | Combinations of therapeutic agents for treating cancer |
| EP2268612B1 (en) | 2008-03-24 | 2014-08-20 | Novartis AG | Arylsulfonamide-based matrix metalloprotease inhibitors |
| KR101252349B1 (ko) | 2008-03-26 | 2013-04-08 | 노파르티스 아게 | 데아세틸라제 ｂ의 히드록사메이트-기재 억제제 |
| CN101362784A (zh) * | 2008-10-06 | 2009-02-11 | 山东大学 | 埃博霉素苷类化合物和以其为活性成分的组合物及其应用 |
| WO2010083617A1 (en) | 2009-01-21 | 2010-07-29 | Oncalis Ag | Pyrazolopyrimidines as protein kinase inhibitors |
| US20110281917A1 (en) | 2009-01-29 | 2011-11-17 | Darrin Stuart | Substituted Benzimidazoles for the Treatment of Astrocytomas |
| PE20121048A1 (es) | 2009-06-26 | 2012-08-25 | Novartis Ag | Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17 |
| US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
| JP5781510B2 (ja) | 2009-08-12 | 2015-09-24 | ノバルティス アーゲー | ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用 |
| AU2010284972A1 (en) | 2009-08-20 | 2012-03-08 | Novartis Ag | Heterocyclic oxime compounds |
| EP2470502A1 (en) | 2009-08-26 | 2012-07-04 | Novartis AG | Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators |
| CA2779935A1 (en) | 2009-11-04 | 2011-05-12 | Novartis Ag | Heterocyclic sulfonamide derivatives useful as mek inhibitors |
| CN102648188A (zh) | 2009-12-08 | 2012-08-22 | 诺瓦提斯公司 | 杂环磺酰胺衍生物 |
| US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| CU24130B1 (es) | 2009-12-22 | 2015-09-29 | Novartis Ag | Isoquinolinonas y quinazolinonas sustituidas |
| AU2011255647A1 (en) | 2010-05-18 | 2012-11-15 | Cerulean Pharma Inc. | Compositions and methods for treatment of autoimmune and other diseases |
| UA112517C2 (uk) | 2010-07-06 | 2016-09-26 | Новартіс Аг | Тетрагідропіридопіримідинові похідні |
| JP2013537210A (ja) | 2010-09-16 | 2013-09-30 | ノバルティス アーゲー | １７α−ヒドロキシラーゼ／Ｃ１７，２０−リアーゼ阻害剤 |
| BR112013018534B1 (pt) | 2011-01-20 | 2021-04-06 | Board Of Regents, The University Of Texas System | Agente de contraste, seus métodos de preparação, e produto de combinação |
| EP2673277A1 (en) | 2011-02-10 | 2013-12-18 | Novartis AG | [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase |
| EA023064B1 (ru) | 2011-04-28 | 2016-04-29 | Новартис Аг | ИНГИБИТОРЫ 17α-ГИДРОКСИЛАЗЫ/C-ЛИАЗЫ |
| EP2718276A1 (en) | 2011-06-09 | 2014-04-16 | Novartis AG | Heterocyclic sulfonamide derivatives |
| CA2837840C (en) | 2011-06-10 | 2020-08-04 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| US8859535B2 (en) | 2011-06-20 | 2014-10-14 | Novartis Ag | Hydroxy substituted isoquinolinone derivatives |
| EP2721007B1 (en) | 2011-06-20 | 2015-04-29 | Novartis AG | Cyclohexyl isoquinolinone compounds |
| AU2012277391A1 (en) | 2011-06-27 | 2013-12-19 | Novartis Ag | Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives |
| CN102863474A (zh) | 2011-07-09 | 2013-01-09 | 陈小平 | 一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用 |
| US9062045B2 (en) | 2011-09-15 | 2015-06-23 | Novartis Ag | Triazolopyridine compounds |
| CN102993239A (zh) | 2011-09-19 | 2013-03-27 | 陈小平 | 离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物 |
| CN104080787B (zh) | 2011-11-29 | 2016-09-14 | 诺华股份有限公司 | 吡唑并吡咯烷化合物 |
| SI2794600T1 (en) | 2011-12-22 | 2018-03-30 | Novartis Ag | 2,3-Dihydro-benzo (1,4) oxazine derivatives and related compounds as phosphoinositide-3 kinase inhibitors (PI3K) for the treatment, e.g. rheumatoid arthritis |
| EP2794594A1 (en) | 2011-12-22 | 2014-10-29 | Novartis AG | Quinoline derivatives |
| BR112014015308A8 (pt) | 2011-12-23 | 2017-06-13 | Novartis Ag | compostos para inibição da interação de bcl2 com contrapartes de ligação |
| KR20140107573A (ko) | 2011-12-23 | 2014-09-04 | 노파르티스 아게 | Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물 |
| US20140350014A1 (en) | 2011-12-23 | 2014-11-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
| CN104125953A (zh) | 2011-12-23 | 2014-10-29 | 诺华股份有限公司 | 用于抑制bcl2与结合配偶体相互作用的化合物 |
| EP2794591A1 (en) | 2011-12-23 | 2014-10-29 | Novartis AG | Compounds for inhibiting the interaction of bcl2 with binding partners |
| KR101372563B1 (ko) | 2011-12-26 | 2014-03-14 | 주식회사 삼양바이오팜 | 에포틸론 함유물질로부터 에포틸론 ａ와 ｂ의 추출 및 정제 방법 |
| JO3357B1 (ar) | 2012-01-26 | 2019-03-13 | Novartis Ag | مركبات إيميدازوبيروليدينون |
| EA201492005A1 (ru) | 2012-05-15 | 2015-04-30 | Новартис Аг | Бензамидные производные для ингибирования активности abl1, abl2 и bcr-abl1 |
| AU2013261127B2 (en) | 2012-05-15 | 2015-03-12 | Novartis Ag | Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 |
| MX357305B (es) | 2012-05-15 | 2018-07-04 | Novartis Ag | Compuestos y composiciones para inhibir la actividad de abl-1, abl-2, y bcr-abl1. |
| AU2013261130A1 (en) | 2012-05-15 | 2014-10-23 | Novartis Ag | Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 |
| CN104321325B (zh) | 2012-05-24 | 2016-11-16 | 诺华股份有限公司 | 吡咯并吡咯烷酮化合物 |
| US9789193B2 (en) | 2012-06-15 | 2017-10-17 | The Brigham And Women's Hospital, Inc. | Compositions for treating cancer and methods for making the same |
| EP3150582A1 (en) | 2012-10-02 | 2017-04-05 | Gilead Sciences, Inc. | Inhibitors of histone demethylases |
| EP2924044B1 (en) | 2012-11-17 | 2018-10-31 | Beijing Shuobai Pharmaceutical Co., LTD | Platinum compound of malonic acid derivative having leaving group containing amino or alkylamino |
| TW201422625A (zh) | 2012-11-26 | 2014-06-16 | Novartis Ag | 二氫－吡啶并－□衍生物之固體形式 |
| JP6334553B2 (ja) | 2012-12-10 | 2018-05-30 | メルサナ セラピューティクス，インコーポレイティド | タンパク質−高分子−薬剤コンジュゲート |
| EP2931316B1 (en) | 2012-12-12 | 2019-02-20 | Mersana Therapeutics, Inc. | Hydroxyl-polymer-drug-protein conjugates |
| JO3464B1 (ar) | 2013-01-15 | 2020-07-05 | Astellas Pharma Europe Ltd | التركيبات الخاصة بمركبات التياكوميسين |
| WO2014115080A1 (en) | 2013-01-22 | 2014-07-31 | Novartis Ag | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction |
| US9403827B2 (en) | 2013-01-22 | 2016-08-02 | Novartis Ag | Substituted purinone compounds |
| WO2014128612A1 (en) | 2013-02-20 | 2014-08-28 | Novartis Ag | Quinazolin-4-one derivatives |
| JP6514117B2 (ja) | 2013-02-27 | 2019-05-15 | エピセラピューティクス アーペーエス | ヒストン脱メチル化酵素の阻害剤 |
| US20150018376A1 (en) | 2013-05-17 | 2015-01-15 | Novartis Ag | Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof |
| KR20160018534A (ko) | 2013-06-11 | 2016-02-17 | 바이엘 파마 악티엔게젤샤프트 | Mps-1 키나제 억제제 및 유사분열 억제제를 포함하는 암의 치료를 위한 조합물 |
| UY35675A (es) | 2013-07-24 | 2015-02-27 | Novartis Ag | Derivados sustituidos de quinazolin-4-ona |
| US9227969B2 (en) | 2013-08-14 | 2016-01-05 | Novartis Ag | Compounds and compositions as inhibitors of MEK |
| WO2015022663A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
| WO2015022664A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
| KR20160058889A (ko) | 2013-09-22 | 2016-05-25 | 칼리토르 사이언시즈, 엘엘씨 | 치환된 아미노피리미딘 화합물 및 이용 방법 |
| PL3054992T3 (pl) | 2013-10-11 | 2020-01-31 | Asana Biosciences, Llc | Koniugaty białko-polimer-lek |
| KR102087850B1 (ko) | 2013-10-11 | 2020-03-12 | 메르사나 테라퓨틱스, 인코포레이티드 | 단백질-고분자-약물 접합체 |
| EP3122728A4 (en) | 2014-03-28 | 2017-10-25 | Calitor Sciences, LLC | Substituted heteroaryl compounds and methods of use |
| JP2017512804A (ja) | 2014-03-31 | 2017-05-25 | ギリアード サイエンシーズ， インコーポレイテッド | ヒストン脱メチル化酵素の阻害剤 |
| WO2015153345A1 (en) | 2014-04-03 | 2015-10-08 | Invictus Oncology Pvt. Ltd. | Supramolecular combinatorial therapeutics |
| MA40470A (fr) | 2014-08-27 | 2016-03-03 | Gilead Sciences Inc | Composés et procédés d'inhibition des histones déméthylases |
| US9938257B2 (en) | 2015-09-11 | 2018-04-10 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
| EP3474901B1 (en) | 2016-06-27 | 2025-08-06 | Tagworks Pharmaceuticals B.V. | Cleavable tetrazine used in bio-orthogonal drug activation |
| US11135307B2 (en) | 2016-11-23 | 2021-10-05 | Mersana Therapeutics, Inc. | Peptide-containing linkers for antibody-drug conjugates |
| JP7320458B2 (ja) | 2017-06-22 | 2023-08-03 | メルサナ セラピューティクス インコーポレイテッド | 薬物担持ポリマースキャフォールドおよびタンパク質－ポリマー－薬物コンジュゲートを製造する方法 |
| US10683297B2 (en) | 2017-11-19 | 2020-06-16 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
| JP7450541B2 (ja) | 2018-01-20 | 2024-03-15 | サンシャイン・レイク・ファーマ・カンパニー・リミテッド | 置換アミノピリミジン化合物及び使用方法 |
| AU2019262520B2 (en) | 2018-05-04 | 2025-07-10 | Tagworks Pharmaceuticals B.V. | Tetrazines for high click conjugation yield in vivo and high click release yield |
| CA3099421C (en) | 2018-05-04 | 2025-05-06 | Tagworks Pharmaceuticals B V | COMPOUNDS INCLUDING A BINDER TO INCREASE TRANSCYCLOOCTENE STABILITY |
| CA3117050A1 (en) | 2018-10-29 | 2020-05-07 | Mersana Therapeutics, Inc. | Cysteine engineered antibody-drug conjugates with peptide-containing linkers |
| FR3087650B1 (fr) | 2018-10-31 | 2021-01-29 | Bio Even | Flavine adenine dinucleotide (fad) pour son utilisation pour la prevention et/ou le traitement de cancer |
| IL289094A (en) | 2019-06-17 | 2022-02-01 | Tagworks Pharmaceuticals B V | Tetrazines for increasing the speed and yield of the "click release" reaction |
| EP4382129A3 (en) | 2019-06-17 | 2024-07-03 | Tagworks Pharmaceuticals B.V. | Compounds for fast and efficient click release |
| KR20240099150A (ko) | 2021-09-06 | 2024-06-28 | 베락사 바이오테크 게엠베하 | 진핵생물에서의 유전자 코드 확장을 위한 신규 아미노아실-tRNA 합성효소 변이체 |
| DK4186529T3 (da) | 2021-11-25 | 2025-08-25 | Veraxa Biotech Gmbh | Forbedrede antistof-payload-konjugater (apc) fremstillet ved stedspecifik konjugering ved hjælp af genetisk kodeudvidelse |
| US20250144255A1 (en) | 2021-11-25 | 2025-05-08 | Veraxa Biotech Gmbh | Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion |
| JP2024546769A (ja) | 2021-12-08 | 2024-12-26 | ヨーロピアン モレキュラー バイオロジー ラボラトリー | 標的複合体の調製のための親水性テトラジン機能化ペイロード |
| EP4314031B1 (en) | 2022-02-15 | 2024-03-13 | Tagworks Pharmaceuticals B.V. | Masked il12 protein |
| CN119836306A (zh) | 2022-07-15 | 2025-04-15 | 费恩治疗有限公司 | 与cdcp1结合的抗体药物缀合物和其用途 |
| IL320221A (en) | 2022-10-12 | 2025-06-01 | Tagworks Pharmaceuticals B V | Strained bicyclo-nonanes |
| WO2024153789A1 (en) | 2023-01-20 | 2024-07-25 | Basf Se | Stabilized biopolymer composition, their manufacture and use |
| WO2024191293A1 (en) | 2023-03-10 | 2024-09-19 | Tagworks Pharmaceuticals B.V. | Trans-cyclooctene with improved t-linker |
| WO2025021929A1 (en) | 2023-07-27 | 2025-01-30 | Veraxa Biotech Gmbh | Hydrophilic trans-cyclooctene (hytco) compounds, constructs and conjugates containing the same |
| EP4512395A1 (en) | 2023-08-21 | 2025-02-26 | Bio Even | Composition comprising flavin adenine dinucleotide (fad), l-gsh, atp and myristic acid, alone or with a drug |
| WO2025056807A1 (en) | 2023-09-15 | 2025-03-20 | Basf Se | Stabilized biopolymer composition, their manufacture and use |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| WO2025174248A1 (en) | 2024-02-16 | 2025-08-21 | Tagworks Pharmaceuticals B.V. | Trans-cyclooctenes with "or gate" release |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0358606A3 (de) | 1988-09-09 | 1990-10-31 | Gesellschaft für Biotechnologische Forschung mbH (GBF) | Mikrobiologisches Verfahren zur Herstellung agrarchemisch verwendbarer mikrobizider makrozyklischer Lactonderivate |
| GB8909737D0 (en) | 1989-04-27 | 1989-06-14 | Shell Int Research | Thiazole derivatives |
| DE4138042C2 (de) * | 1991-11-19 | 1993-10-14 | Biotechnolog Forschung Gmbh | Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel |
| ATE201990T1 (de) | 1993-03-05 | 2001-06-15 | Hexal Ag | Kristallinische cyclodextrin-einschlusskomplexe von ranitidinhxdrochlorid und verfahren |
| EP0739339A1 (en) * | 1994-01-11 | 1996-10-30 | The Scripps Research Institute | Chemical switching of taxo-diterpenoids between low solubility active forms and high solubility inactive forms |
| EP0873341B1 (de) | 1995-11-17 | 2003-09-10 | Gesellschaft für biotechnologische Forschung mbH (GBF) | Epothilonderivate, herstellung und verwendung |
| DE19542986A1 (de) * | 1995-11-17 | 1997-05-22 | Biotechnolog Forschung Gmbh | Epothilon-Derivate und deren Verwendung |
| DE19639456A1 (de) | 1996-09-25 | 1998-03-26 | Biotechnolog Forschung Gmbh | Epothilon-Derivate, Herstellung und Mittel |
| DE19636343C1 (de) | 1996-08-30 | 1997-10-23 | Schering Ag | Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B |
| DE19645362A1 (de) | 1996-10-28 | 1998-04-30 | Ciba Geigy Ag | Verfahren zur Herstellung von Epothilon A und B und Derivaten |
| DE19645361A1 (de) | 1996-08-30 | 1998-04-30 | Ciba Geigy Ag | Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II |
| EP0923583A1 (de) * | 1996-08-30 | 1999-06-23 | Novartis AG | Verfahren zur herstellung von epothilonen und zwischenprodukte innerhalb des verfahrens |
| US5969145A (en) * | 1996-08-30 | 1999-10-19 | Novartis Ag | Process for the production of epothilones and intermediate products within the process |
| DE59711647D1 (de) * | 1996-11-18 | 2004-06-24 | Biotechnolog Forschung Gmbh | Epothilon d, dessen herstellung und dessen verwendung als cytostatisches mittel bzw. als pflanzenschutzmittel |
| US6515016B2 (en) | 1996-12-02 | 2003-02-04 | Angiotech Pharmaceuticals, Inc. | Composition and methods of paclitaxel for treating psoriasis |
| US6204388B1 (en) * | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| AU756699B2 (en) * | 1996-12-03 | 2003-01-23 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| US6441186B1 (en) * | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
| US6660758B1 (en) * | 1996-12-13 | 2003-12-09 | The Scripps Research Institute | Epothilone analogs |
| US6380394B1 (en) * | 1996-12-13 | 2002-04-30 | The Scripps Research Institute | Epothilone analogs |
| DE19701758A1 (de) | 1997-01-20 | 1998-07-23 | Wessjohann Ludgar A Dr | Epothilone-Synthesebausteine |
| AU736062B2 (en) * | 1997-02-25 | 2001-07-26 | Gesellschaft Fur Biotechnologische Forschung Mbh | Epothilones which are modified in the side chain |
| US5828449A (en) | 1997-02-26 | 1998-10-27 | Acuity Imaging, Llc | Ring illumination reflective elements on a generally planar surface |
| DE19713970B4 (de) | 1997-04-04 | 2006-08-31 | R&D-Biopharmaceuticals Gmbh | Epothilone-Synthesebausteine II - Prenylderivate |
| WO1998047891A1 (de) | 1997-04-18 | 1998-10-29 | Studiengesellschaft Kohle Mbh | Selektive olefinmetathese von bi- oder polyfunktionellen substraten in komprimiertem kohlendioxid als reaktionsmedium |
| DE19720312A1 (de) | 1997-05-15 | 1998-11-19 | Hoechst Ag | Zubereitung mit erhöhter in vivo Verträglichkeit |
| DE19821954A1 (de) | 1997-05-15 | 1998-11-19 | Biotechnolog Forschung Gmbh | Verfahren zur Herstellung eines Epothilon-Derivats |
| DE19726627A1 (de) | 1997-06-17 | 1998-12-24 | Schering Ag | Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon |
| US6605599B1 (en) * | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
| US6384230B1 (en) | 1997-07-16 | 2002-05-07 | Schering Aktiengesellschaft | Thiazole derivatives, method for their production and use |
| US7407975B2 (en) | 1997-08-09 | 2008-08-05 | Bayer Schering Pharma Ag | Epothilone derivatives, method for producing same and their pharmaceutical use |
| WO1999039694A2 (en) | 1998-02-05 | 1999-08-12 | Novartis Ag | Compositions containing organic compounds |
| US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
| FR2775187B1 (fr) | 1998-02-25 | 2003-02-21 | Novartis Ag | Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo |
| JP2002504540A (ja) | 1998-02-25 | 2002-02-12 | スローン−ケッタリング インスティトゥート フォア キャンサー リサーチ | エポチロンの合成、その中間体およびそのアナログ |
| DE19826988A1 (de) * | 1998-06-18 | 1999-12-23 | Biotechnolog Forschung Gmbh | Epothilon-Nebenkomponenten |
| AU5036999A (en) | 1998-06-30 | 2000-01-17 | Schering Aktiengesellschaft | Epothilon derivatives, their preparation process, intermediate products and their pharmaceutical use |
| US6410301B1 (en) * | 1998-11-20 | 2002-06-25 | Kosan Biosciences, Inc. | Myxococcus host cells for the production of epothilones |
| AU768220B2 (en) | 1998-11-20 | 2003-12-04 | Kosan Biosciences, Inc. | Recombinant methods and materials for producing epothilone and epothilone derivatives |
| JP2002533346A (ja) | 1998-12-22 | 2002-10-08 | ノバルティス アクチエンゲゼルシャフト | エポシロン誘導体およびそれらの抗腫瘍剤としての使用 |
| US6780620B1 (en) | 1998-12-23 | 2004-08-24 | Bristol-Myers Squibb Company | Microbial transformation method for the preparation of an epothilone |
| US6596875B2 (en) * | 2000-02-07 | 2003-07-22 | James David White | Method for synthesizing epothilones and epothilone analogs |
| EE200100431A (et) | 1999-02-18 | 2002-12-16 | Schering Aktiengesellschaft | 16-halogenoepotilooni derivaadid, nende valmistamismeetod ja farmatseutiline kasutamine |
| DK1157023T3 (da) * | 1999-02-22 | 2004-03-29 | Bristol Myers Squibb Co | C-21-modificerede epothiloner |
| US6211412B1 (en) * | 1999-03-29 | 2001-04-03 | The University Of Kansas | Synthesis of epothilones |
| AR023792A1 (es) | 1999-04-30 | 2002-09-04 | Bayer Schering Pharma Ag | Derivados 6-alquenilo- y 6-alquinilo-epotilona, los procedimientos para prepararlos y su empleo en productos farmaceuticos |
| TWI310684B (en) * | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
| US6589968B2 (en) * | 2001-02-13 | 2003-07-08 | Kosan Biosciences, Inc. | Epothilone compounds and methods for making and using the same |
| US6489314B1 (en) * | 2001-04-03 | 2002-12-03 | Kosan Biosciences, Inc. | Epothilone derivatives and methods for making and using the same |
| US6906188B2 (en) * | 2001-04-30 | 2005-06-14 | State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University | Method for synthesizing epothilones and epothilone analogs |
| WO2003029195A1 (en) * | 2001-09-28 | 2003-04-10 | Sumika Fine Chemicals Co., Ltd. | Intermediates for epothilone derivative and process for producing these |
| US6884608B2 (en) * | 2001-12-26 | 2005-04-26 | Bristol-Myers Squibb Company | Compositions and methods for hydroxylating epothilones |
| TW200303202A (en) | 2002-02-15 | 2003-09-01 | Bristol Myers Squibb Co | Method of preparation of 21-amino epothilone derivatives |
| US6921769B2 (en) * | 2002-08-23 | 2005-07-26 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| EP2287168B1 (en) | 2002-09-23 | 2013-02-13 | Bristol-Myers Squibb Company | Methods for the preparation, isolation and purification of epothilone B, and X-ray crystal structures of epothilone B |
-
1997
- 1997-11-18 DE DE59711647T patent/DE59711647D1/de not_active Expired - Lifetime
- 1997-11-18 BR BRPI9713363-9A patent/BR9713363B1/pt not_active IP Right Cessation
- 1997-11-18 CZ CZ20041118A patent/CZ303422B6/cs not_active IP Right Cessation
- 1997-11-18 ES ES03016552T patent/ES2312695T3/es not_active Expired - Lifetime
- 1997-11-18 ES ES97951233T patent/ES2221692T5/es not_active Expired - Lifetime
- 1997-11-18 DK DK03016552T patent/DK1367057T3/da active
- 1997-11-18 PL PL333435A patent/PL193229B1/pl unknown
- 1997-11-18 JP JP52320898A patent/JP4274583B2/ja not_active Expired - Lifetime
- 1997-11-18 HU HU0000497A patent/HU229833B1/hu unknown
- 1997-11-18 DE DE59712968T patent/DE59712968D1/de not_active Expired - Lifetime
- 1997-11-18 CA CA2269118A patent/CA2269118C/en not_active Expired - Lifetime
- 1997-11-18 PT PT97951233T patent/PT941227E/pt unknown
- 1997-11-18 NZ NZ335383A patent/NZ335383A/xx not_active IP Right Cessation
- 1997-11-18 AT AT03016552T patent/ATE408612T1/de active
- 1997-11-18 IL IL12955897A patent/IL129558A/en not_active IP Right Cessation
- 1997-11-18 RU RU99113031/04A patent/RU2198173C2/ru active
- 1997-11-18 PT PT03016552T patent/PT1367057E/pt unknown
- 1997-11-18 DK DK97951233T patent/DK0941227T5/da active
- 1997-11-18 AU AU54837/98A patent/AU753546B2/en not_active Expired
- 1997-11-18 CN CNB2005100062827A patent/CN100344627C/zh not_active Expired - Lifetime
- 1997-11-18 EP EP97951233A patent/EP0941227B2/de not_active Expired - Lifetime
- 1997-11-18 CN CNB971998140A patent/CN1196698C/zh not_active Expired - Lifetime
- 1997-11-18 WO PCT/EP1997/006442 patent/WO1998022461A1/de not_active Ceased
- 1997-11-18 AT AT97951233T patent/ATE267197T1/de active
- 1997-11-18 CZ CZ0175099A patent/CZ296164B6/cs not_active IP Right Cessation
- 1997-11-18 KR KR10-1999-7004302A patent/KR100538095B1/ko not_active Expired - Lifetime
- 1997-11-18 EP EP03016552A patent/EP1367057B1/de not_active Expired - Lifetime
-
1998
- 1998-01-21 TW TW086117334A patent/TW408119B/zh not_active IP Right Cessation
-
1999
- 1999-05-14 NO NO19992338A patent/NO319984B1/no not_active IP Right Cessation
-
2004
- 2004-11-12 US US10/988,328 patent/US7067544B2/en not_active Expired - Fee Related
-
2005
- 2005-10-26 CY CY0500058A patent/CY2542B1/xx unknown
-
2006
- 2006-04-27 US US11/412,536 patent/US20060264482A1/en not_active Abandoned
-
2008
- 2008-04-28 US US12/110,781 patent/US20080293784A1/en not_active Abandoned
-
2009
- 2009-03-24 US US12/409,823 patent/US7846952B2/en not_active Expired - Fee Related
- 2009-05-01 US US12/434,078 patent/US7759375B2/en not_active Expired - Fee Related
-
2010
- 2010-12-06 US US12/961,447 patent/US8076490B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2542B1 (en) | Epothilone c, d, e and f, production process, and their use as cytostatic as well as phytosanitary agents | |
| DK0643689T3 (da) | Forbedret fremgangsmåde til syntese af (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoat | |
| DK0553213T3 (da) | Fremgangsmåde til fremstilling af (4R-cis)-1,1-dimethylethyl-6-cyanomethyl-2,2-dimethyl-1,3-dioxan- 4-acetat | |
| AU2002221693A1 (en) | Epothilone synthesis components iii and iv: asymmetrically substituted acyloins and acyloin derivatives, method for the production thereof and method for the production of epithilone b, d and epothilone derivatives | |
| DE50203844D1 (de) | Verfahren zur herstellung von 1-olefinen mit palladiumcarbenverbindungen | |
| EP0745610A3 (en) | Process for preparing anti-obesity protein | |
| EP0837139A3 (en) | Two step conversion of vegetable protein isoflavone conjugates to isoflavone aglucones | |
| ES2160895T3 (es) | Produccion de un suero proteinico vegetal enriquecido con isoflavonas agluconicas. | |
| ERKEL et al. | Antibiotics from basidiomycetes XLI clavicoronic acid, a novel inhibitor of reverse transcriptases from Clavicorona pyxidata (pers. ex fr.) doty | |
| IT1250692B (it) | Procedimento per la preparazione di demetilepipodofillotossina- beta-d-glucosidi. | |
| WO2002030983A3 (de) | Bikunin enthaltende plasmafraktion, verfahren zu ihrer herstellung und ihrer verwendung | |
| AU665641B2 (en) | Cereal product | |
| EP0861838A3 (en) | Process and intermediates for preparing cryptophycin compounds | |
| AU1438992A (en) | Water extraction components produced by adhesive bonds, process for their manufacture and their use | |
| EP1396482A4 (en) | PROCESS FOR THE PREPARATION OF ADAMANTAN AND ANALOGUE THEREOF | |
| US5907047A (en) | Papyracillic acid, method for preparation and its use as synthon for bioactive substances | |
| DE50013193D1 (de) | Verfahren zur Herstellung von Allyltrichlorsilan | |
| SI0758635T1 (en) | Process for the isomerisation of olefins | |
| NO924102L (no) | Fremgangsmaate for fremstilling av substituerte vinylbenzener | |
| WO2000018777A3 (en) | Method for synthesizing c-glycosides of ulosonic acids | |
| Gimenez et al. | Biotechnologie, University ofKaiserslautern. | |
| ES1030366U (es) | Rebosadero perfeccionado, para bañeras y similares. |